Overview

Gender

male

Investor Type

Investment Partner

Axel Polack is a General Partner at the Joint Polish Investment Fund. Before JPIF Dr. Polack was from 2000 to 2014 a key member of the Life Science team at TVM Capital, which raised more than 680m€ in venture capital and accomplished 67 investments, 18 IPOs (“initial public offerings”) and 15 trade sales. Prior to his career in venture capital he was involved in business management as General Manager and basic biomedical research as Deputy Chairman of a large research institute. He has a proven track record in venture capital and early stage company building.

During his time as board member and lead investor representative Genetix Inc. developed into high flying bluebird bio Inc. which attracted 101m$ through an Initial Public Offering (IPO) at NASDAQ in June 2013. Due to break through successes in gene therapy the company reached today a Market Cap of more than 5b$.

As long term board member of Alzheimer ’s disease specialist Probiodrug AG (PBD) was instrumental for the preparation of its IPO on Euronext Amsterdam in October 2014. It represents one of the rare and successful IPOs of German biotech in recent years.